Brokerages Set Stryker Co. (NYSE:SYK) Price Target at $300.86

Stryker Co. (NYSE:SYK – Get Rating) has been given an average rating of “Hold” by the twenty-eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $300.86.

SYK has been the subject of several research reports. Piper Sandler raised their price objective on shares of Stryker from $280.00 to $310.00 in a research report on Tuesday, May 2nd. Citigroup lifted their price target on Stryker from $290.00 to $326.00 and gave the stock a “buy” rating in a research note on Monday, April 3rd. Argus lifted their target price on shares of Stryker from $270.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, February 21st. Loop Capital upped their price target on shares of Stryker from $290.00 to $312.00 and gave the company a “buy” rating in a research report on Monday, April 17th. Finally, Jefferies Financial Group raised their price objective on shares of Stryker from $320.00 to $345.00 in a research note on Tuesday, May 2nd.

Stryker Stock Down 0.2 %

Stryker stock opened at $285.12 on Tuesday. Stryker has a one year low of $188.84 and a one year high of $306.56. The firm has a market capitalization of $108.23 billion, a P/E ratio of 41.50, a P/E/G ratio of 3.01 and a beta of 0.94. The company has a 50-day simple moving average of $284.33 and a 200-day simple moving average of $258.77. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.99 and a current ratio of 1.73.

Stryker (NYSE:SYK – Get Rating) last announced its earnings results on Monday, May 1st. The medical technology company reported $2.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.00 by $0.14. The firm had revenue of $4.80 billion during the quarter, compared to analyst estimates of $4.56 billion. Stryker had a net margin of 13.86% and a return on equity of 22.17%. Stryker’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.97 EPS. As a group, equities analysts expect that Stryker will post 10.17 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 5,459 shares of Stryker stock in a transaction that occurred on Tuesday, February 28th. The shares were sold at an average price of $263.27, for a total transaction of $1,437,190.93. Following the transaction, the director now owns 13,537 shares of the company’s stock, valued at approximately $3,563,885.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.90% of the stock is owned by insiders.

Institutional Trading of Stryker

A number of institutional investors have recently modified their holdings of SYK. Stratos Wealth Advisors LLC boosted its holdings in Stryker by 1.0% during the first quarter. Stratos Wealth Advisors LLC now owns 3,632 shares of the medical technology company’s stock worth $1,037,000 after purchasing an additional 37 shares during the last quarter. Perigon Wealth Management LLC grew its holdings in Stryker by 1.5% during the first quarter. Perigon Wealth Management LLC now owns 2,500 shares of the medical technology company’s stock worth $714,000 after purchasing an additional 37 shares during the period. Ameritas Advisory Services LLC increased its position in Stryker by 2.4% during the fourth quarter. Ameritas Advisory Services LLC now owns 1,609 shares of the medical technology company’s stock worth $393,000 after buying an additional 38 shares during the last quarter. Chicago Partners Investment Group LLC raised its stake in Stryker by 2.5% in the fourth quarter. Chicago Partners Investment Group LLC now owns 1,606 shares of the medical technology company’s stock valued at $438,000 after buying an additional 39 shares during the period. Finally, Stockman Wealth Management Inc. boosted its stake in shares of Stryker by 3.0% during the 1st quarter. Stockman Wealth Management Inc. now owns 1,370 shares of the medical technology company’s stock worth $391,000 after acquiring an additional 40 shares during the period. 77.10% of the stock is currently owned by institutional investors.

Stryker Company Profile

(Get Rating)

Stryker Corp. is a medical technology company, which engages in the provision of innovative products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery.